Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuttle, Katherine R., McKinney, T. Dwight, Davidson, Jaime A., Anglin, Greg, Harper, Kristine D., Botros, Fady T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347883/
https://www.ncbi.nlm.nih.gov/pubmed/27766728
http://dx.doi.org/10.1111/dom.12816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347883/
https://www.ncbi.nlm.nih.gov/pubmed/27766728
http://dx.doi.org/10.1111/dom.12816

Ejemplares similares